EQS-News: ADC Therapeutics doses first patient in a phase I clinical trial of ADCT-502 in patients with advanced solid tumors with HER2 expression

Nachricht vom 19.05.2017 (www.4investors.de) -


EQS Group-News: ADC Therapeutics SA / Schlagwort(e): Studie

ADC Therapeutics doses first patient in a phase I clinical trial of ADCT-502 in patients with advanced solid tumors with HER2 expression
19.05.2017 / 07:46
ADC Therapeutics Doses First Patient in a Phase I Clinical Trial of ADCT-502 in Patients with Advanced Solid Tumors with HER2 Expression
 

- Trial to provide data on safety, tolerability, pharmacokinetics and efficacy

- ADCT-502 represents ADC Therapeutic's fourth ADC program in clinical trials

Lausanne, Switzerland, May 19, 2017 - ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced that the first patient has been dosed in a Phase I clinical trial to evaluate its antibody drug conjugate (ADC) ADCT-502 in patients with advanced solid tumors with HER2 expression.

The two stage, open-label Phase Ia / Ib clinical trial will evaluate the safety, tolerability, pharmacokinetics and efficacy of ADCT-502 in patients with advanced solid tumors with HER2 expression. The first stage (Phase Ia) is a dose escalation phase which will recruit patients at leading clinical centres across the US and EU, and will seek to determine the recommended dose of ADCT-502. The second consecutive stage (Phase Ib), has the objective to confirm the safety and efficacy profile for ADCT-502 in expanded patient cohorts in multiple potential cancer indications.

ADCT-502 combines a humanized monoclonal antibody targeting the protein HER2 with a pyrrolobenzodiazepine (PBD) warhead. The HER2 surface protein is expressed at high or low levels in a variety of different tumor types, including breast cancer, gastric and gastroesophageal cancers. In preclinical studies, ADCT-502 exhibited strong dose-dependent anti-tumor activity at low single doses against both low and high HER2 expressing tumors. Given the substantial prevalence of HER2 expression in a range of cancers, ADCT-502 will be evaluated in patients with non-small cell lung cancer (NSCLC), bladder, biliary tract, and ovarian cancer, for which HER2 targeted therapies are not yet approved.

Dr. Jay Feingold, Chief Medical Officer and Senior Vice President of Clinical Development at ADCT said: "This is the fourth ADC we have put into the clinic in just over two years. Dosing the first patient in this trial with ADCT-502 is an important milestone for us and could pave the way for a better treatment regimen for patients. The trial will give us vital data on safety, tolerability and dosing. Our preclinical studies suggest ADCT-502 may provide significant clinical benefit for patients suffering from a variety of tumor types which are known to express HER2 in a significant proportion of patients. We are exploring this potential in lung, bladder and biliary tract cancers further within this study as well as in the more established indications of breast and gastric cancer."

Dr. Kyriakos Papadopoulos, Senior Clinical Investigator of START and one of the investigators of the study said: "Tremendous advances have been made in the treatment of HER2 expressing cancers, particularly gastroesophageal and breast cancers, in the past 20 years. However, a significant portion of this patient population still fail to respond or relapse with currently available therapies. Having seen the effects of other pyrrolobenzodiazepine ADCs in various tumour types in recent years, we eagerly anticipate the results of this study."

ADC Therapeutics has four PBD-based antibody drug conjugates in six ongoing Phase I clinical trials in the USA and in Europe.

About ADCT-502
ADCT-502 is an investigational antibody drug conjugate (ADC) composed of the humanized monoclonal antibody trastuzumab directed against the human epidermal growth factor receptor 2 (HER2). The antibody is site-specifically conjugated to the PBD-based linker-drug tesirine. Once bound to the HER2 receptor on the cell surface, ADCT-502 is internalized into the cell where enzymes release the PBD-based warhead. HER2 is a well-established, clinically validated target expressed in a wide variety of solid tumors, including breast, gastric, esophageal, bladder and lung cancer. ADCT-502 is being evaluated in an ongoing Phase I clinical trial in patients with advanced solid tumors with HER2 expression.

About ADC Therapeutics
Founded in 2012, ADC Therapeutics SA (ADCT) is an oncology drug development company that specializes in the development of proprietary antibody drug conjugates (ADCs) targeting major types of hematological malignancies and solid tumors. The Company's ADCs are highly targeted biopharmaceutical drugs that combine monoclonal antibodies specific to surface antigens present on particular tumor cells with a novel class of highly potent pyrrolobenzodiazepine (PBD) based warheads via a chemical linker. Its three lead programs, ADCT-301, ADCT-402, and ADCT-502 are in five Phase I clinical trials in the USA and in Europe. ADCT enjoys strong relationships with world class partners, including Astrazeneca and its global biologics research and development arm, MedImmune. The Company is based in Lausanne, Switzerland and has operations in London, San Francisco and New Jersey (www.adctherapeutics.com).

For more information please contact:
Dr. Chris Martin
Chief Executive Officer
chris.martin@adctherapeutics.com
Tel.: +41 (0) 21 653 0200

Alexandre Müller
Dynamics Group
amu@dynamicsgroup.ch
Tel: +41 (0) 43 268 3231


Zusatzmaterial zur Meldung:Dokument: http://n.eqs.com/c/fncls.ssp?u=OQKVVFCTEMDokumenttitel: ADCT 502 HER2 19052017
Ende der Medienmitteilung



575551  19.05.2017 





PfeilbuttonAURELIUS: „2017 wird das beste Jahr in unserer Unternehmensgeschichte” - Exklusiv-Interview
PfeilbuttonHanseYachts: „Unser Verkaufsapparat läuft inzwischen wie eine geölte Maschine“ - Exklusiv-Interview
PfeilbuttonNOXXON Pharma: DEWB-Beteiligung steht vor wichtigen Meilensteinen - Exklusiv-Interview


+++ Exklusive Interviews und Analysen - gratis in Ihre Mailbox! +++

Tragen Sie sich jetzt für unseren kostenlosen 4investors Newsletter ein.


Bestätigungslink nicht per Mail bekommen? Bitte kontrollieren Sie Ihren Spamordner!

Der 4investors Newsletter erscheint unregelmäßig, i.d.R. 2 bis 6 Mal pro Monat. Wir geben ihre Mailadresse an keinen Dritten weiter! Sie können den kostenlosen 4investors Newsletter jederzeit problemlos wieder abbestellen.
comments powered by Disqus


Aktuelle Nachrichten aus der 4investors-Redaktion

20.10.2017 - Metro sieht Impulse unter anderem im Onlinegeschäft
20.10.2017 - Uniper will Kraftwerk im Sommer stilllegen
20.10.2017 - Nordex Aktie: Jetzt wird es richtig kritisch!
20.10.2017 - CR Capital Real Estate: Kapitalherabsetzung wird umgesetzt
20.10.2017 - RIB Software: Neuer US-Auftrag
20.10.2017 - Corestate kauft ehemaligen Sitz von „4711” in Köln
20.10.2017 - co.don platziert sämtliche Aktien aus Kapitalerhöhung
20.10.2017 - Befesa startet nach Varta-Erfolg mit dem IPO
20.10.2017 - Villeroy + Boch: Rekord-Auftragslage in der Bad-Sparte
20.10.2017 - Software AG: Turbulente Zeiten - Quartalszahlen


Chartanalysen

20.10.2017 - MBB Aktie: Boden nach dem „Aumann-Schock” in Sicht?
20.10.2017 - E.On Aktie: Was passiert hier gerade?
20.10.2017 - Morphosys Aktie: Die Lage spitzt sich zu!
20.10.2017 - BYD und Geely: Beide Aktie bleiben absturzgefährdet, aber...
19.10.2017 - Evotec Aktie: Das war es dann wohl, oder?
19.10.2017 - BYD und Geely: Aktien unter Druck - das wird jetzt ganz eng für die Bullen!
19.10.2017 - Medigene Aktie: Aus der Traum?
19.10.2017 - Commerzbank Aktie: Alles steht auf des Messers Schneide!
18.10.2017 - Evotec Aktie: Das kann noch gefährlich werden
18.10.2017 - BYD Aktie: Heißer Poker zwischen Bullen und Bären


Analystenschätzungen

19.10.2017 - Aixtron Aktie: Das Aus für die Bullen?
19.10.2017 - Commerzbank Aktie: Das dürfte den Bullen gar nicht in den Kram passen
19.10.2017 - Bayer Aktie bekommt Kaufempfehlung
19.10.2017 - Puma Aktie: Neue Expertenstimmen
19.10.2017 - SAP: Reaktionen auf die Zahlen
19.10.2017 - Volkswagen und Porsche: Aktien leiden unter Goldman Sachs
19.10.2017 - Aixtron Aktie: Kursziel fast verdreifacht, aber…
19.10.2017 - Morphosys Aktie: Sehr gute Nachrichten!
18.10.2017 - Unicredit: Plus 20 Prozent
18.10.2017 - BMW: 43 Prozent sind machbar


Kolumnen

20.10.2017 - Xi Jinping stärkt seine Macht und die Macht der Kommunistischen Partei - Commerzbank Kolumne
20.10.2017 - Haushaltsentwurf passiert den US-Senat - National-Bank
20.10.2017 - Daimler Aktie: Neuer Aufwärtstrend hat sich etabliert - UBS Kolumne
20.10.2017 - DAX: Die Volatilität zieht deutlich an - UBS Kolumne
19.10.2017 - US-Wohnungsmarkt ohne Anzeichen einer Überhitzung - Commerzbank Kolumne
19.10.2017 - Erklärt Katalonien heute Morgen endgültig die Unabhängigkeit? - National-Bank
19.10.2017 - China: Wachstum glänzt auf den ersten Blick – im Hintergrund gärt es - VP Bank Kolumne
19.10.2017 - Vonovia Aktie: Neues Allzeithoch bestätigt Aufwärtstrend - UBS Kolumne
19.10.2017 - DAX: Der Widerstand ist gebrochen - UBS Kolumne
18.10.2017 - Asien bleibt stark - AXA IM Kolumne

Werbung

All Right Reserved by minimalthemes - ©2014 Stoffels & Barck GbR